Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
You are being asked to take part in this study because you have advanced melanoma.
The goal of this clinical research study is to learn if oral azacitidine (CC-486) and
pembrolizumab (MK-3475) can help to control melanoma. The safety of this drug combination
will also be studied.
This is an investigational study. Azacitidine is FDA approved and commercially available for
the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia. Pembrolizumab is
FDA approved and commercially available for the treatment of melanoma. It is considered
investigational to use this drug combination to treat melanoma.
The study doctor will explain how the study drugs are designed to work.
Up to 71 participants will be enrolled in this study. All will take part at MD Anderson.